By Lisa Thompson NYSE:DSS READ THE FULL DSS RESEARCH REPORT DSS (NYSE:DSS) continued to make progress in Q1 to reduce its cash burn by spinning off Sharing Services Global. Although Sharing has not year reported its March quarter we believe it contributed about $3 million in revenues and the same amount in operating expenses to
Tilray Brands, Inc. NEW YORK and LEAMINGTON, Ontario, June 10, 2025 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, today announced that the vote for an amendment of the Company’s Fifth
Merus N.V. UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2025 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced the launch of a proposed underwritten public offering of its common shares (the “Offer
TORONTO, May 15, 2025–(BUSINESS WIRE)–Kontrol Technologies Corp. (CBOE.CA:KNR) (OTCQB:KNRLF) (FSE:1K8) (“Kontrol Technologies” or “Kontrol” or “Company”) announces its results for the three months ended March 31, 2025. A complete set of the Financial Statements and Management’s Discussion & Analysis have been filed on SEDAR (www.sedarplus.ca). “As of Q1 2025 we have streamlined the Company and
Instil Bio Enrollment of 1L NSCLC patients in China trial of AXN-2510/IMM2510 in combination with chemotherapy is ongoing with initial clinical data by ImmuneOnco expected in 2H 2025 Initiation of U.S. clinical study of AXN-2510/IMM2510 in combination with chemotherapy in 1L NSCLC anticipated before the end of 2025, assuming receipt of necessary regulatory approvals DALLAS,
Jelmyto Sales: $20.3 million in Q1 2025, 8% year-over-year growth. Revenue Growth: Driven by 12% underlying demand growth. R&D Expenses: $19.9 million in Q1 2025, up from $15.5 million in Q1 2024. SG&A Expenses: $35 million in Q1 2025, up from $27.3 million in Q1 2024. Net Loss: $43.8 million or $0.92 per share in
Generation Bio Co. – Company continues to advance its strategy to develop first-in-class treatments for T cell-driven autoimmune diseases using its cell-targeted lipid nanoparticle (ctLNP) technology to deliver siRNA – Lead target and portfolio strategy to be announced mid-2025 – Cash balance of $157.6 million expected to fund operations into 2H 2027 CAMBRIDGE, MASS., May
Total Revenue: $112.6 million, up 1.6% year over year. Non-GAAP Gross Margin: 35.8%. Adjusted EBITDA: $14.9 million, up 17% year over year. Non-GAAP EPS: $0.88, up 13% year over year. North America Revenue: $49.4 million, up 11% year over year. International Revenue: $63.2 million, down 5% year over year. GAAP Operating Expenses: $30 million, down
Revenue: $139 million in Q1 2025, representing 28% growth over Q1 2024. Crysvita Revenue: $103 million, with 25% growth over 2024; $41 million from North America, $55 million from Latin America and Turkey, $7 million from Europe. Dojolvi Revenue: $17 million, consistent with steady growth. Evkeeza Revenue: $11 million, with increasing demand following launches outside
~$1.05 billion of cash, cash equivalents and marketable securities as of March 31, 2025, and an updated cash runway guidance into 2029; commercial readiness activities ongoing Over 300 patients enrolled in darovasertib and crizotinib registrational 1L HLA-A2-negative MUM trial; targeting median PFS results by YE 2025 to enable potential accelerated approval filing Successful FDA Type